Immunohistochemistry Stains

The ARUP Immunohistochemistry Laboratory performs more than 175 stains on formalin-fixed, paraffin-embedded tissues/cellblocks. These stains are used to detect the presence, abundance, and localization of specific proteins to aid in determining the direction of differentiation in neoplasms with similar morphology as well as to provide prognostic or therapeutic information, among other applications.

This lab is pathologist oriented, providing a stain and return service only, without interpretation, to our client pathologists to assist in their diagnostic studies. Most stains are returned the next day. The available stains are listed under the Stain and Return Immunohistochemistry tab. If interpretation is needed, please order a consultation.

To order a surgical pathology consultation, please use test code 2013263 Consultation, Surgical Pathology or 2013258 Consultation, Hematopathology. For more information, call (801)581-2507. Please include pertinent clinical history and surgical pathology report.

The Immunohistochemistry Laboratory has a menu of immunohistochemistry tests for which we will provide interpretation by one of our ARUP faculty pathologists. A list of these tests can be found under the Immunohistochemistry Tests tab. The ARUP Immunohistochemistry Laboratory is an NSABP-approved laboratory for the testing of breast markers.
All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Test # Test Name Test Keywords Test Description
2003430 Adenovirus by Immunohistochemistry Adenovirus
  • Specific to all subtypes of adenovirus
2003427 Adrenocorticotropic Hormone (ACTH) by Immunohistochemistry Acromegaly, Cushing Syndrome, Hypopituitarism, Tumor Markers, Endocrine/Adrenal Cancer, Lung Cancer, Pituitary Cancer, thymoma, medullary thyroid carcinoma Adrenocorticotropic hormone:
  • Subclassifies pituitary adenomas
2003433 Pan Cytokeratin (AE1,3) by Immunohistochemistry Glucagonoma, Somatostatinoma, VIPoma, Gastrinoma, Pancreatic Neuroendocrine Tumors (NET), Mesothelioma, Testicular Cancer, Tumor Markers, Synovial Sarcoma, Epithelial Sarcoma, Carcinoma, Adenocarcinoma, Tumor Markers, AE1,3
  • Cytokeratin antibody cocktail for acidic and basic cytokeratins
2003418 Alpha-1-Antichymotrypsin (A1ACT) by Immunohistochemistry Pancreatic Acinar Carcinoma, Alpha-1 Antitrypsin Deficiency, Tumor Markers Alpha 1 ACT:
  • Aids in identifying hepatomas and some germ cell neoplasms
  • Histiocyte marker for normal/neoplastic tissue
2003424 Alpha-1-Antitrypsin (AAT) by Immunohistochemistry Alpha-1-Antitrypsin Deficiency (AAT), Hemochromatosis Alpha 1 AT:
  • Expressed by cells of histolytic origin
  • Aids in identifying germ cell and histolytic neoplasms, as well as embryonal and some lung carcinomas
2003436 Alpha-1-Fetoprotein (AFP) by Immunohistochemistry Testicular Germ Cell tumor, Ovarian Germ Cell Tumor, Brain Tumors, Tumor Markers
  • Expressed by neoplastic liver and gonad tissue
  • Aids in identifying bladder carcinomas, yolk sac tumors, some germ cell tumors and a high proportion of hepatocellular carcinoma
2003419 Alpha-Synuclein by Immunohistochemistry aSynuclien (SNCA):
  • Demonstrates Lewy bodies in brain cells associated with Parkinson's and Alzheimer's.
2003439 Anaplastic Lymphoma Kinase 1 (ALK-1) by Immunohistochemistry Sarcoma, T/NK-Cell Lymphomas, B-Cell Lymphomas, Tumor Markers, Non-small cell carcinoma, lung, malignant rhabdoid tumor Anaplastic lymphoma kinase 1:
  • Reacts with the NPM-ALK fusion protein expressed by t(2;5) positive anaplastic large cell lymphomas
2011890 Arginase 1 by Immunohistochemistry
  • Aides in the distinction of HCC from other hepatocellular and non-hepatocellular mass lesions, as well as in cases of metastatic carcinoma and other benign and malignant nonhepatocellular mimics
2014499 ATRX by Immunohistochemistry Prostate Cancer, prostate epithelium, breast, ductal epithelium, gastric mucosa, glial cells
  • Expression of ATRX is implicated in cancer pathogenesis and is useful in the diagnosis of astrocytic gliomas. Its specificity and prevalence in lower-grade gliomas with an IDH-mutation argue for thorough characterization of associated signaling networks to facilitate therapeutic development.
  • Mutation or loss of alpha-thalassemia/mental retardation syndrome X-linked (ATRX) expression has been described in anaplastic gliomas. ATRX loss is a hallmark of astrocytic tumors and defines a subgroup of astrocytic tumors with a favorable prognosis.